Opinion
- Author:
- Katherine Tucker, MD
Publish date: December 20, 2024
Vulvovaginal melanoma often goes unrecognized until it has reached an advanced stage. Increased awareness about these rare forms of melanoma is vit...
Opinion
- Author:
- Katherine Tucker, MD
Publish date: June 18, 2024
Checkpoint inhibitors improve outcomes in women with advanced endometrial cancer and an immunotherapy and antivascular endothelial growth factor co...
Opinion
- Author:
- Katherine Tucker, MD
Publish date: May 14, 2024
When The Cancer Genome Atlas performed genomic, transcriptomic, and proteomic characterization of endometrial carcinomas, they identified four cate...
Opinion
- Author:
- Katherine Tucker, MD
Publish date: March 29, 2023
Ovarian-sparing procedures should be offered to patients in the setting of borderline ovarian tumors, with the understanding that they are counsele...
Opinion
- Author:
- Katherine Tucker, MD
Publish date: January 24, 2023
Secondary debulking surgery has been studied since the 1980s with mixed results; these data have shown that the largest barrier to care has been ap...
Opinion
- Author:
- Katherine Tucker, MD
Publish date: November 18, 2022
Treatment of high-grade vulvar intraepithelial neoplasia should be driven by the clinical characteristics of the vulvar lesions, patients’ preferen...
Opinion
- Author:
- Katherine Tucker, MD
Publish date: September 27, 2022
Second uterine evacuation for treatment of nonmetastatic, low-risk postmolar GTN is a reasonable treatment option and one that should be considered...
Opinion
- Author:
- Katherine Tucker, MD
Publish date: August 17, 2022
Given the data we have, ERT does not appear to significantly affect oncologic outcomes in low-risk, early-stage endometrial cancer survivors.
Opinion
- Author:
- Katherine Tucker, MD
Publish date: May 24, 2022
It is important to have conversations with patients before ordering a CA-125 (or other serum biomarkers) about potential results and their effect o...
